© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 13, 1074-1080,
July 5, 2000
© 2000 Oxford University Press
Randomized Trial of Paclitaxel Plus Supportive Care Versus Supportive Care for Patients With Advanced Non-Small-Cell Lung Cancer
Affiliations of authors: M. Ranson, H. Anderson, N. Thatcher, Christie Hospital and Wythenshawe Hospital, Manchester, U.K.; N. Davidson, North Middlesex Hospital, London, U.K.; M. Nicolson, Aberdeen Royal Infirmary, U.K.; S. Falk, Bristol Oncology Centre, U.K.; J. Carmichael, University of Nottingham, U.K.; P. Lopez, North-Eastern Ontario Regional Cancer Centre, Sudbury, Canada; N. Gustafson, A. Jeynes, G. Gallant, T. Washington, Bristol-Myers Squibb Co., Princeton, NJ.
Correspondence to: Malcolm Ranson, Ph.D., F.R.C.P., Cancer Research Campaign Department of Medical Oncology, Christie Hospital National Health Service Trust, Wilmslow Rd., Manchester, U.K. M20 4BX (e-mail: malcolm.ranson{at}man.ac.uk).
Background: In phase II trials, paclitaxel has been shown to have antitumor activity in patients with advanced non-small-cell lung cancer (NSCLC). However, the survival and quality-of-life (QOL) benefits of paclitaxel used as a single agent compared with supportive care alone have not been assessed in a randomized clinical trial. Methods: A total of 157 patients with stage IIIB or IV NSCLC who had received no prior chemotherapy were randomly assigned to receive either best supportive care alone (78 patients) or paclitaxel plus supportive care (79 patients). Paclitaxel was administered as a 3-hour intravenous infusion every 3 weeks. Supportive care included palliative radiotherapy and supportive therapy with corticosteroids, antibiotics, analgesics, antiemetics, transfusions, and other symptomatic therapy as required. The primary end point of the study was survival. Time to disease progression, response rate, adverse events, and QOL were secondary end points. Results: Pretreatment characteristics were evenly distributed between the two arms. Survival was statistically significantly better in the paclitaxel plus supportive care arm than in the supportive care alone arm (two-sided P = .037) (median survival = 6.8 months versus 4.8 months). Cox multivariate analysis showed paclitaxel plus supportive care to be statistically significantly associated with improved survival (two-sided P = .048). QOL was similar for both treatment arms, except for the functional activity score of the Rotterdam Symptom Checklist, where QOL data statistically significantly favored the paclitaxel plus supportive care arm (two-sided P = .043). Conclusion: The addition of paclitaxel to best supportive care significantly improved survival and time to disease progression compared with best supportive care in patients with advanced NSCLC and may improve some aspects of QOL.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. I. Cherny, A. P. Abernethy, F. Strasser, R. Sapir, D. Currow, and S. Y. Zafar Improving the Methodologic and Ethical Validity of Best Supportive Care Studies in Oncology: Lessons From a Systematic Review J. Clin. Oncol., November 10, 2009; 27(32): 5476 - 5486. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. H. Kim, K. Kubota, K. Goto, K. Yoh, S. Niho, H. Ohmatsu, N. Saijo, and Y. Nishiwaki A Phase I Study of Gemcitabine and Carboplatin in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2 Jpn. J. Clin. Oncol., September 1, 2009; 39(9): 576 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J-P. Sculier and D. Moro-Sibilot First- and second-line therapy for advanced nonsmall cell lung cancer Eur. Respir. J., April 1, 2009; 33(4): 915 - 930. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Berhoune, E. Banu, F. Scotte, P. Prognon, S. Oudard, and B. Bonan Therapeutic Strategy for Treatment of Metastatic Non-Small Cell Lung Cancer Ann. Pharmacother., November 1, 2008; 42(11): 1640 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
NSCLC Meta-Analyses Collaborative Group Chemotherapy in Addition to Supportive Care Improves Survival in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data From 16 Randomized Controlled Trials J. Clin. Oncol., October 1, 2008; 26(28): 4617 - 4625. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar, and M. J. Hawkins Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer Ann. Onc., August 1, 2006; 17(8): 1263 - 1268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Booton, P. Lorigan, H. Anderson, S. Baka, L. Ashcroft, M. Nicolson, M. O'Brien, D. Dunlop, K. O'Byrne, V. Laurence, et al. A phase III trial of docetaxel/carboplatin versus mitomycin C/ifosfamide/cisplatin (MIC) or mitomycin C/vinblastine/cisplatin (MVP) in patients with advanced non-small-cell lung cancer: a randomised multicentre trial of the British Thoracic Oncology Group (BTOG1) Ann. Onc., July 1, 2006; 17(7): 1111 - 1119. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, M. Aapro, A. Ardizzoni, L. Balducci, F. De Marinis, K. Kelly, T. Le Chevalier, C. Manegold, F. Perrone, R. Rosell, et al. Treatment of Advanced Non-Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel J. Clin. Oncol., May 1, 2005; 23(13): 3125 - 3137. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bunn Jr Platinums in Lung Cancer: Sufficient or Necessary? J. Clin. Oncol., May 1, 2005; 23(13): 2882 - 2883. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Waechter, J. Passweg, M. Tamm, M. Brutsche, R. Herrmann, and M. Pless Significant Progress in Palliative Treatment of Non-small Cell Lung Cancer in the Past Decade Chest, March 1, 2005; 127(3): 738 - 747. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. G. Azzoli, D. G. Pfister, D. H. Johnson, and M. R. Somerfield In Reply: J. Clin. Oncol., December 15, 2004; 22(24): 5020 - 5021. [Full Text] [PDF]
|
|
|
|
|
|
R. R. Jennens, R. de Boer, L. Irving, D. L. Ball, and M. A. Rosenthal Differences of Opinion: A Survey of Knowledge and Bias Among Clinicians Regarding the Role of Chemotherapy in Metastatic Non-small Cell Lung Cancer Chest, December 1, 2004; 126(6): 1985 - 1993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials Ann. Onc., December 1, 2004; 15(12): 1782 - 1789. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Earle Outcomes Research in Lung Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Rigas Taxane-Platinum Combinations in Advanced Non-Small Cell Lung Cancer: A Review Oncologist, June 2, 2004; 9(suppl_2): 16 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Shanafelt, C. Loprinzi, R. Marks, P. Novotny, and J. Sloan Are Chemotherapy Response Rates Related to Treatment-Induced Survival Prolongations in Patients With Advanced Cancer? J. Clin. Oncol., May 15, 2004; 22(10): 1966 - 1974. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Prommer Gefitinib: A new agent in palliative care American Journal of Hospice and Palliative Medicine, May 1, 2004; 21(3): 222 - 227. [Abstract] [PDF]
|
|
|
|
|
|
C. M. Rocha Lima, N. A. Rizvi, C. Zhang, J. E. Herndon 2nd, J. Crawford, R. Govindan, G. W. King, and M. R. Green Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC Ann. Onc., March 1, 2004; 15(3): 410 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Gridelli, A. Ardizzoni, T. Le Chevalier, C. Manegold, F. Perrone, N. Thatcher, N. van Zandwijk, M. Di Maio, O. Martelli, and F. De Marinis Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel Ann. Onc., March 1, 2004; 15(3): 419 - 426. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003 J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353. [Full Text] [PDF]
|
|
|
|
 |
|
 R. S. Herbst and P. A. Bunn Jr. Targeting the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Clin. Cancer Res., December 1, 2003; 9(16): 5813 - 5824. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. F. Smit, J. P.A.M. van Meerbeeck, P. Lianes, C. Debruyne, C. Legrand, F. Schramel, H. Smit, R. Gaafar, B. Biesma, C. Manegold, et al. Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975 J. Clin. Oncol., November 1, 2003; 21(21): 3909 - 3917. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bottomley, F. Efficace, R. Thomas, V. Vanvoorden, and S. H. Ahmedzai Health-Related Quality of Life in Non-Small-Cell Lung Cancer: Methodologic Issues in Randomized Controlled Trials J. Clin. Oncol., August 1, 2003; 21(15): 2982 - 2992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Booton, M Jones, and N Thatcher Lung cancer * 7: Management of lung cancer in elderly patients Thorax, August 1, 2003; 58(8): 711 - 720. [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, F. Piantedosi, S. Barbera, F. Ferrau, E. Piazza, F. Rosetti, et al. Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial J Natl Cancer Inst, March 5, 2003; 95(5): 362 - 372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer Chest, January 1, 2003; 123 (2009): 226S - 243S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.M.F. Kruijtzer, J.H.M. Schellens, J. Mezger, M.E. Scheulen, U. Keilholz, J.H. Beijnen, H. Rosing, R.A.A. Mathot, S. Marcus, H. van Tinteren, et al. Phase II and Pharmacologic Study of Weekly Oral Paclitaxel Plus Cyclosporine in Patients With Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., December 1, 2002; 20(23): 4508 - 4516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.M.F. Kruijtzer, J.H. Beijnen, and J.H.M. Schellens Improvement of Oral Drug Treatment by Temporary Inhibition of Drug Transporters and/or Cytochrome P450 in the Gastrointestinal Tract and Liver: An Overview Oncologist, December 1, 2002; 7(6): 516 - 530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rosell, U. Gatzemeier, D. C. Betticher, U. Keppler, H. N. Macha, R. Pirker, P. Berthet, J. L. Breau, P. Lianes, M. Nicholson, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial Ann. Onc., October 1, 2002; 13(10): 1539 - 1549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bunn Jr Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why? J. Clin. Oncol., September 15, 2002; 20(90001): 23s - 33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Bunn Jr Treatment of Advanced Non-Small-Cell Lung Cancer With Two-Drug Combinations J. Clin. Oncol., September 1, 2002; 20(17): 3565 - 3567. [Full Text] [PDF]
|
|
|
|
 |
|
 Chemotherapy and non-small-cell lung cancer DTB, February 1, 2002; 40(2): 9 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Clegg, D A Scott, P Hewitson, M Sidhu, and N Waugh Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review Thorax, January 1, 2002; 57(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Isla, R. Rosell, J. J. Sanchez, A. Carrato, E. Felip, C. Camps, A. Artal, J. L. Gonzalez-Larriba, P. Azagra, V. Alberola, et al. Phase II Trial of Paclitaxel Plus Gemcitabine in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer J. Clin. Oncol., February 15, 2001; 19(4): 1071 - 1077. [Abstract] [Full Text] [PDF]
|
|